These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38312931)

  • 1. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.
    Doran SJ; Sawyer RP
    Front Neurosci; 2024; 18():1326784. PubMed ID: 38312931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
    Withington CG; Turner RS
    Front Neurol; 2022; 13():862369. PubMed ID: 35401412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
    Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
    Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lecanemab: Appropriate Use Recommendations.
    Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
    J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.
    Söderberg L; Johannesson M; Gkanatsiou E; Nygren P; Fritz N; Zachrisson O; Rachalski A; Svensson AS; Button E; Dentoni G; Osswald G; Lannfelt L; Möller C
    Sci Rep; 2024 May; 14(1):10868. PubMed ID: 38740836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.
    Yoon CH; Groff C; Criss O
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
    Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
    Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
    Honig LS; Barakos J; Dhadda S; Kanekiyo M; Reyderman L; Irizarry M; Kramer LD; Swanson CJ; Sabbagh M
    Alzheimers Dement (N Y); 2023; 9(1):e12377. PubMed ID: 36949897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
    Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
    JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Ebell MH; Barry HC; Baduni K; Grasso G
    Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of Amyloid-Related Imaging Abnormalities (ARIA).
    Urbach H; Linn J; Hattingen E; Fiebach J
    Rofo; 2024 Apr; 196(4):363-369. PubMed ID: 37995736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.